Literature DB >> 33975152

Differential expression of insulin receptor substrate-1(IRS-1) in visceral and subcutaneous adipose depots of morbidly obese subjects undergoing bariatric surgery in a tertiary care center in north India; SNP analysis and correlation with metabolic profile.

Mukti Sharma1, Sandeep Aggarwal2, Umakant Nayar2, Naval Kishore Vikram3, Anoop Misra4, Kalpana Luthra5.   

Abstract

BACKGROUND: /aim: Abdominal obesity and associated metabolic consequences are a burgeoning problem in Asian Indians and studying their genetic predisposition is important. This study is aimed at assessing variations in Insulin receptor substrate-1 (IRS-1), its expression at regional fat-depots (visceral and subcutaneous) in morbidly obese patients, and correlation with genotype-phenotype traits.
METHODS: Gene expression of IRS-1 in paired adipose tissue from 35 morbidly obese subjects (BMI) > 40 kg/m2) with co-morbidities and 15 controls (BMI<25 kg/m2), undergoing bariatric/elective abdominal surgery, respectively was determined by quantitative real time PCR. Genotyping of IRS-1Gly972Arg (n = 436) (rs 1801278) was performed by PCR-RFLP. Metabolic parameters were assessed. Full length sequencing of IRS-1 was performed to identify known/novel variations.
RESULTS: A marked reduction in IRS-1 expression was observed in visceral as compared to subcutaneous adipose tissue of morbidly obese subjects (p = 0.02). Homozygous variant of IRS-1 Gly972Arg was absent and there was no association with obesity or insulin resistance. A salient finding of this study was identification of two new variants in IRS-1 gene, representing G > A (codon 1102) encoding Glu > Lys and a deletion of (A) at codon 658 in morbidly obese subjects with insulin resistance.
CONCLUSIONS: Observation of a substantially lower expression of IRS-1 for first time in visceral adipose tissue of morbidly obese subjects is suggestive of predictive role of IRS-1 expression in insulin responsiveness of visceral adipose tissue. New variants in IRS-1, a non-synonymous mutation and a deletion should be evaluated further for their role in development of obesity and/orT2DM.
Copyright © 2021 Diabetes India. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Bariatric surgery; Gene expression; IRS-1; Novel variations; Subcutaneous abdominal adipose tissue (SCAT); Visceral adipose tissue (VAT)

Mesh:

Substances:

Year:  2021        PMID: 33975152     DOI: 10.1016/j.dsx.2021.04.014

Source DB:  PubMed          Journal:  Diabetes Metab Syndr        ISSN: 1871-4021


  4 in total

1.  Genomic analysis to screen potential genes and mutations in children with non-syndromic early onset severe obesity: a multicentre study in Turkey.

Authors:  Aysehan Akinci; Altan Kara; Aykut Özgür; Doga Turkkahraman; Soner Aksu
Journal:  Mol Biol Rep       Date:  2021-11-30       Impact factor: 2.316

2.  Combination of Single-Nucleotide Polymorphisms and Preoperative Body Mass Index to Predict Weight Loss After Laproscopic Sleeve Gastrectomy in Chinese Patients with Body Mass Index ≥ 32.5 kg/m2.

Authors:  Liang Wang; Guangzhong Xu; Chenxu Tian; Qing Sang; Chengyuan Yu; Qiqige Wuyun; Zheng Wang; Weijian Chen; Buhe Amin; Dezhong Wang; Guanyang Chen; Dongbo Lian; Nengwei Zhang
Journal:  Obes Surg       Date:  2022-10-24       Impact factor: 3.479

3.  Effect of Carica papaya on IRS-1/Akt Signaling Mechanisms in High-Fat-Diet-Streptozotocin-Induced Type 2 Diabetic Experimental Rats: A Mechanistic Approach.

Authors:  Jeane Rebecca Roy; Coimbatore Sadagopan Janaki; Selvaraj Jayaraman; Vijayalakshmi Periyasamy; Thotakura Balaji; Madhavan Vijayamalathi; Vishnu Priya Veeraraghavan
Journal:  Nutrients       Date:  2022-10-08       Impact factor: 6.706

4.  NDRG1 Activity in Fat Depots Is Associated With Type 2 Diabetes and Impaired Incretin Profile in Patients With Morbid Obesity.

Authors:  Iurii Stafeev; Igor Sklyanik; Elizaveta Mamontova; Svetlana Michurina; Ekaterina Shestakova; Kamil Yah'yaev; Anatoliy Yurasov; Denis Masnikov; Maria Sineokaya; Elizaveta Ratner; Alexander Vorotnikov; Mikhail Menshikov; Yelena Parfyonova; Marina Shestakova
Journal:  Front Endocrinol (Lausanne)       Date:  2021-12-09       Impact factor: 5.555

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.